News and Views
Nature Medicine 14, 1315 - 1316 (2008)
doi:10.1038/nm1208-1315
Targeting RAS and PI3K in lung cancer
Julian Downward1
-
Julian Downward is at the Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK.
e-mail: downward@cancer.org.uk
Abstract
The phosphoinositide 3-kinase (PI3K) and RAS oncoproteins are activated in many major tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to shrink tumors in transgenic mouse cancer models. The drug also blocks RAS-induced lung tumors when combined with an inhibitor of mitogen-activated protein kinase kinase (pages 1351–1356).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam1 −/− miceOncogene Original Article
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in MiceJournal of Cerebral Blood Flow & Metabolism Original Article
See all 9 matches for Research
